BRPI0415713A - mio-inositol hexafosfato para uso tópico - Google Patents

mio-inositol hexafosfato para uso tópico

Info

Publication number
BRPI0415713A
BRPI0415713A BRPI0415713-3A BRPI0415713A BRPI0415713A BR PI0415713 A BRPI0415713 A BR PI0415713A BR PI0415713 A BRPI0415713 A BR PI0415713A BR PI0415713 A BRPI0415713 A BR PI0415713A
Authority
BR
Brazil
Prior art keywords
myo
inositol hexaphosphate
topical use
nucleators
heterogeneous
Prior art date
Application number
BRPI0415713-3A
Other languages
English (en)
Inventor
Felicia Grases Freixedas
Joan Perello Bestard
Bernat Isern Amengual
Rafael Prieto Almirall
Ant Nia Costa Bauza
Original Assignee
Sanifit S L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit S L Lab filed Critical Sanifit S L Lab
Publication of BRPI0415713A publication Critical patent/BRPI0415713A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MIO-INOSITOL HEXAFOSFATO PARA USO TóPICO". A presente invenção refere-se a uma composição que inclui mio-inositol hexafosfato aplicado através de administração tópica para utilização no tratamento ou prevenção de uma doença associada com o desenvolvimento de nucleantes heterogêneos em um tecido mole. A dita composição pode ser usada para fabricação de uma droga para o tratamento de uma doença associada com o desenvolvimento de nucleantes heterogêneos em um tecido mole.
BRPI0415713-3A 2003-11-07 2004-11-03 mio-inositol hexafosfato para uso tópico BRPI0415713A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302600A ES2232302B1 (es) 2003-11-07 2003-11-07 Myo-inositol hexafosfato para uso topico.
PCT/IB2004/003588 WO2005044278A1 (en) 2003-11-07 2004-11-03 Myo-inositol hexaphosphate for topical use

Publications (1)

Publication Number Publication Date
BRPI0415713A true BRPI0415713A (pt) 2006-12-19

Family

ID=34566008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415713-3A BRPI0415713A (pt) 2003-11-07 2004-11-03 mio-inositol hexafosfato para uso tópico

Country Status (15)

Country Link
US (1) US20070066574A1 (pt)
EP (1) EP1680128B1 (pt)
JP (1) JP4786543B2 (pt)
AT (1) ATE353655T1 (pt)
BR (1) BRPI0415713A (pt)
CA (1) CA2544963C (pt)
CY (1) CY1106574T1 (pt)
DE (1) DE602004004817T2 (pt)
DK (1) DK1680128T3 (pt)
ES (2) ES2232302B1 (pt)
MX (1) MXPA06005043A (pt)
PL (1) PL1680128T3 (pt)
PT (1) PT1680128E (pt)
SI (1) SI1680128T1 (pt)
WO (1) WO2005044278A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
CA2488230C (en) 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates, and methods of use thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
ES2532591T3 (es) * 2005-03-18 2015-03-30 Normoxys, Inc. Sal de calcio y de sodio de mio-inositol 1,6:2,3:4,5 tripirofosfato para el tratamiento del cáncer
ES2272191B1 (es) * 2005-10-14 2008-04-01 Universitat De Les Illes Balears Utilizacion del fitato para el tratamiento del agua.
ES2280136B1 (es) 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
AU2008246061A1 (en) * 2007-05-01 2008-11-06 Normoxys, Inc. Erythropoietin complementation or replacement
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
WO2019176693A1 (ja) * 2018-03-15 2019-09-19 国立大学法人広島大学 骨外組織における骨形成関連因子又は石灰化関連因子の発現抑制剤
BR112021006004A2 (pt) 2018-10-11 2021-06-29 Sanifit Therapeutics S.A. inositol fosfatos para o tratamento de calcificações ectópicas.
EP3917535A1 (en) 2019-01-30 2021-12-08 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in increasing tissular perfusion
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
WO2024023359A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2024023360A1 (en) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip5 substituted compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934002A (en) * 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US6359194B1 (en) * 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5536499A (en) * 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5614511A (en) * 1996-03-11 1997-03-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for treating itchy skin
JP3623430B2 (ja) * 2000-07-06 2005-02-23 築野ライスファインケミカルズ株式会社 抗酸化性組成物
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
EP1327443A1 (en) * 2001-12-21 2003-07-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic or preventing agent for the diseases caused by a decrease in the expression level of the klotho protein

Also Published As

Publication number Publication date
CY1106574T1 (el) 2012-01-25
DK1680128T3 (da) 2007-06-11
DE602004004817D1 (de) 2007-03-29
EP1680128A1 (en) 2006-07-19
ATE353655T1 (de) 2007-03-15
US20070066574A1 (en) 2007-03-22
JP4786543B2 (ja) 2011-10-05
DE602004004817T2 (de) 2007-11-22
ES2232302A1 (es) 2005-05-16
CA2544963A1 (en) 2005-05-19
ES2232302B1 (es) 2006-08-01
MXPA06005043A (es) 2007-03-15
ES2282920T3 (es) 2007-10-16
CA2544963C (en) 2010-03-30
WO2005044278A1 (en) 2005-05-19
JP2007510710A (ja) 2007-04-26
PL1680128T3 (pl) 2007-07-31
EP1680128B1 (en) 2007-02-14
SI1680128T1 (sl) 2007-08-31
PT1680128E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
BRPI0408490A (pt) composições que compreendem ácidos graxos e aminoácidos
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
AR088110A2 (es) Uso de un inmunoconjugado que comprende un anticuerpo anti-erbb2 para la manufactura de un medicamento
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
BRPI0517500A (pt) compostos, uso de uma composição, composição farmacêutica, composição cosmética, uso não-terapêutico de uma composição cosmética e processo cosmético para melhorar a aparência da pele
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0114927A (pt) Composição de gel farmacêutica substancialmente não aquosa para aplicação na pele, e, uso da composição
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BRPI0411451A (pt) formas de dosagens orais de memantina
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BRPI0408295A (pt) uso de um composto
BRPI0510137A (pt) medicamentos contendo n-sulfamoil-n'-arilpiperazinas para a profilaxia ou tratamento da obesidade e condições relacionadas
ECSP077843A (es) Tratamiento o prevención del prurito
BRPI0415215B8 (pt) uso de polifenol na preparação de medicamento
BRPI0511305A (pt) método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BRPI0516811A (pt) compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014.